Nizatidin: Pharmakologisches und klinisches Profil eines neuen H2-Rezeptor-Antagonisten

Free sample

Die Stellung der H2-Rezeptor-Antagonisten ist - mehr als ein Jahrzehnt nach ihrer Einführung in die Therapie säurebedingter Erkrankungen - unangefochten. H2-Blocker sind die am häufigsten eingesetzten Ulkus-Therapeutika und die Substanzgruppe der ersten Wahl in der Behandlung des Erst- und des Rezidivulkus. Im vorliegenden Buch wird der im Titel bezeichnete neue H2-Rezeptor-Antagonist hinsichtlich seiner pharmakologischen, toxikologischen und therapeutischen Eigenschaften ausführlich charakterisiert und im besonderen mit dem bisher am weitesten verbreiteten H2-Rezeptor-Antagonisten Ranitidin verglichen. Alle Befunde zeigen, daß Nizatidin dem Ranitidin gleichwertig ist und damit als therapeutische Alternative gleicher Effizienz in der Behandlung säurebedingter Erkrankungen zur Anwendung gelangen kann. Das Buch vermittelt einen ausgezeichneten und lückenlosen Überblick über Pharmakologie, Toxikologie und therapeutische Breite des Nizatidin. Der Leser kann sich darüber hinaus mit den Forschungsarbeiten vertraut machen, die vor Einführung eines neuen Medikamentes notwendig sind. Er erhält eine ausgezeichnete Einführung in das Prinzip und die therapeutische Breite von H2-Rezeptor-Antagonisten, jener Stoffgruppe, die derzeit das wirksamste Prinzip in der Ulkustherapie darstellt.
Read more

Additional Information

Read more
Published on
Mar 7, 2013
Read more
Read more
Read more
Read more
Best For
Read more
Read more
Medical / Gastroenterology
Medical / Hepatology
Medical / Pharmacology
Medical / Pharmacy
Read more
Content Protection
This content is DRM protected.
Read more

Reading information

Smartphones and Tablets

Install the Google Play Books app for Android and iPad/iPhone. It syncs automatically with your account and allows you to read online or offline wherever you are.

Laptops and Computers

You can read books purchased on Google Play using your computer's web browser.

eReaders and other devices

To read on e-ink devices like the Sony eReader or Barnes & Noble Nook, you'll need to download a file and transfer it to your device. Please follow the detailed Help center instructions to transfer the files to supported eReaders.
Wissenschaftliche Studie aus dem Jahr 2012 im Fachbereich Pharmazie, Institute of Pharmaceutical Education Boradi, Sprache: Deutsch, Abstract: Ideally, a drug should arrive rapidly at the site of action (receptor) in the optimum concentration, remain for the desired time, be excluded from other sites, and be rapidly removed when the goal is achieved. Generally, the time course of a dosage form (pharmacokinetics) in man is considered to be controlled by the chemical structure of the drug. Decreasing the rate of absorption and/or changing the dosage form provide a useful adjunct. When it is not feasible or desirable to modify the drug compound on a molecular level, often sought is a product that will require less frequent administration to obtain the required biological activity time profile. It may be desirable to decrease the absorption rate in order to obtain a more acceptable clinical response. The goal of designing sustained release matrix delivery systems is to reduce frequency of dosing or to increase the effectiveness of the drug by localizing at the site of action, reducing the dose required, or providing uniform drug delivery. Hence, designing a sustained release formulation for an antihypertensive drug may prolong therapeutic concentration of drug in the blood and decrease the frequency of dosing and also improve the patient compliance. So in the present study, attempts will be made to formulate a sustained release matrix tablets containing an antihypertensive drug. In December 1843, a patent was granted to the Englishman, William Brockedon for a machine to compress powders to form compacts. This very simple device consisted essentially a hole (or die) bored through which the powder was compressed between the two cylindrical punches; one was inserted into the base of die and at a fixed depth, the other was inserted at the top of die and struck with hammer. The invention was first used to produce compacts of potassium bicarbonate and caught the imagination of no. of pharmaceutical companies. Later, welcome in Britain was the first company to use the term “tablet” to describe the compressed dosage form.
©2018 GoogleSite Terms of ServicePrivacyDevelopersArtistsAbout Google
By purchasing this item, you are transacting with Google Payments and agreeing to the Google Payments Terms of Service and Privacy Notice.